Many of the proposed rate increases of 10 percent or more for Obamacare health insurance plans have been revealed.» Read More
Most parents say they would consider removing their kids from day care if just 25 percent of the children there lacked up-to-date vaccinations.
Celgene's partnering strategy, which has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
New health insurer Oscar will pay customers up to $20 per month to meet goals offered up by a free wearable fitness device.
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
Drug giant Sanofi is juggling legal and regulatory issues surrounding three cases involving alleged payments or inducements to medical providers.
Large employers could find themselves facing worker lawsuits for violating health-reform laws under the Affordable Care Act.
Much of the influenza virus in the U.S. has mutated and this year's vaccine doesn't provide good protection against it, NBC News reports.
A deadly epidemic that could have global implications is quietly sweeping India, and among its many victims are tens of thousands of newborns dying. The New York Times reports.
A lawsuit accuses drug maker Sanofi and top executives, including its ousted CEO, of a million-dollar kickback scheme to promote diabetes drug sales.
Business has slowed down on HealthCare.gov, the federal Obamacare health insurance marketplace, data shows.
As Equinox expands overseas and integrates its acquisition of LA Fitness, the gym chain's president explains strategy and what's changing the industry.
Honeywell CEO David Cote was surprised by the EEOC lawsuit regarding his company's wellness program, which the Obama administration encourages.
Johnson & Johnson has hired Goldman Sachs to explore a sale of its artificial sweetener Splenda, sources familiar with the matter told Reuters.
Biogen Idec said its experimental medicine for Alzheimer's disease showed promise, prompting it to move "aggressively" into the most advanced stage of studies.
Fatalities, infections and other "hospital-acquired conditions" have plunged, and Obamacare may have helped, health officials say.
Ebola was just a wake-up call for a more serious health threat, says Barry I. Eistenstein, a doctor and senior VP at Cubist Pharmaceuticals.
Google-backed genetic testing service 23andMe is launching in the U.K., with the CEO pledging that data would not be shared with Google.
A report suggests that traffic at the Obamacare market that offers insurance to employees of small businesses is off to a less-than-inspiring start.
GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.
Get the best of CNBC in your inbox